Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and sex toys.
Popular Articles

Recession Pushes Cost Of Medicines Up, Pharmacists Lobby For Reform Role
"Even with the Medicare drug benefit, even with the prevalence of low-cost generics, even with loss-leader discounting by big chains, many Americans still find themselves unable to afford the prescription medications that manage their life-threatening conditions," The New York Times reports. In some areas, "the recession has heightened the struggle. National surveys consistently find that as many as a third of respondents say they are not complying with prescriptions because of cost, up from about a fourth three years ago."
buy viagra
A National Autistic Society (NAS) Response To The National Audit Office (NAO) Report On Adults With Autism
Mark Lever, NAS chief executive said; "In the current economic climate the Government cannot possibly ignore the huge cost savings and benefits, identified by their own auditing body, of providing adults with autism with the right support at the right time. Neither the Government, people with autism nor the taxpayer are getting value for money from existing autism services and support, leaving those affected by the condition feeling isolated, ignored and often at breaking point. This is simply unacceptable.
News of the day
Nineteen House Dems Plan To Vote Against Health Reform If Abortion Funding Is Included
Nineteen House Democrats recently sent a letter to House Speaker Nancy Pelosi (D-Calif.) stating that they will not vote for health care reform legislation "unless it explicitly excludes abortion funding from the scope of any government-defined or subsidized health insurance plan," CongressDaily reports. In the letter, the lawmakers wrote that they want to ensure that the Health Benefits Advisory Committee cannot recommend that abortion services be included as part of benefits packages. They wrote, "Without an explicit exclusion, abortion could be included in a government-subsidized health care plan under general health care." The letter was signed by Reps. Dan Boren (Okla.), Bobby Bright (Ala.), Travis Childers (Miss.), Jerry Costello (Ill.), Lincoln Davis (Tenn.), Kathleen Dahlkemper (Pa.), Steve Driehaus (Ohio), Tim Holden (Pa.), Paul Kanjorski (Pa.), Marcy Kaptur (Ohio), Mike McIntyre (N.C.), Charlie Melancon (La.), John Murtha (Pa.), James Oberstar (Minn.), Solomon Ortiz (Texas), Collin Peterson (Minn.), Heath Shuler (N.C.), Bart Stupak (Mich.) and Gene Taylor (Miss.) (CongressDaily, 6/30).
Mental Health

Survival In Prostate Cancer Patients >/=70 Years After Radical Prostatectomy And Comparison To Younger Patients

UroToday.com - In the online issue of the World Journal of Urology, a group headed by Professor Markus Hohenfellner compared the outcomes of radical prostatectomy (RP) in men younger and older than age 70 years. They suggest that in well-selected men over age 70 years, the outcomes are comparable. The study cohort consisted of 626 men who underwent RP at their institution between 1990 and 2006. A total of 526 were younger than 70 years old, and 100 were older than 70 years. The majority underwent radical retropubic RP and 46 underwent a perineal approach. The majority had a pelvic lymphadenectomy performed. Median patient age was 64.4 years, median PSA was 8.9ng/ml, and median follow-up was 5.3 years. For the analysis pre-op PSA, pathologic tumor stage, WHO tumor grading, margin status, time of PSA recurrence, time of distant metastatic recurrence, CaP specific and overall survival were considered. ECOG status was >1 in 7% of the older cohort compared to 2.3% of the younger men. While median age was almost 10 years older, percentage of organ-confined cancer, grade, positive lymph node and positive margin status did not differ. Median PSA-free survival was 10.2 years for the young men and not yet reached for the older men. The 10-year PSA-free survival was 51.8% for the young and 57.4% for the older men. The 10-year metastasis-free survival was 86.9% and 89.7% for the 70 year old patients, respectively. The 10-year prostate cancer specific survival was 92.3% and 97.6% for the young and old men, respectively. Median overall survival was 14 and 12.4 years and 10-year overall survival was 78.1% and 71.2% for the 70 year old patients, respectively. In multivariable analysis, there was no difference in any of the categories for clinical outcome where the age was a risk factor for adverse outcome. Pfitzenmaier J, Pahernik S, Buse S, Haferkamp A, Djakovic N, Hohenfellner M World J Urol. 2009 Apr 26. Epub ahead of print. doi:10.1007/s00345-009-0414-0 Written by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009